DRUG
Bright Minds Biosciences Inc.
Biotechnology
Market Cap$864M
5Y Perf.+286.0%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
DRUG vs CMPS vs ATAI vs MNMD vs CYBN
Revenue, margins, valuation, and 5-year total return — side by side.
CMPS
COMPASS Pathways plc
Medical - Care Facilities
Market Cap$902M
5Y Perf.-75.4%
ATAI
Atai Beckley N.V
Medical - Pharmaceuticals
Market Cap$964M
5Y Perf.-78.3%
MNMD
Mind Medicine (MindMed) Inc.
Biotechnology
Market Cap$2.04B
5Y Perf.-63.5%
CYBN
Cybin Inc.
Biotechnology
Market Cap$304M
5Y Perf.-91.4%
DRUG vs CMPS vs ATAI vs MNMD vs CYBN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | DRUG | CMPS | ATAI | MNMD | CYBN |
|---|---|---|---|---|---|
| Industry | Biotechnology | Medical - Care Facilities | Medical - Pharmaceuticals | Biotechnology | Biotechnology |
| Market Cap | $864M | $902M | $964M | $2.04B | $304M |
| Revenue (TTM) | $0.00 | $0.00 | $3M | $0.00 | $0.00 |
| Net Income (TTM) | $-11M | $-288M | $-154M | $-238M | $-123M |
| Gross Margin | — | — | -259.1% | — | — |
| Operating Margin | — | — | -34.6% | — | — |
| Total Debt | $126K | $21M | $25M | $0.00 | $0.00 |
| Cash & Equiv. | $83M | $150M | $18M | $258M | $135M |
DRUG vs CMPS vs ATAI vs MNMD vs CYBN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
DRUG
CMPS
ATAI
MNMD
CYBN
| Stock | Jun 21 | May 26 | Return |
|---|---|---|---|
| Bright Minds Biosci… (DRUG) | 100 | 386.0 | +286.0% |
| COMPASS Pathways plc (CMPS) | 100 | 24.6 | -75.4% |
| Atai Beckley N.V (ATAI) | 100 | 21.7 | -78.3% |
| Mind Medicine (Mind… (MNMD) | 100 | 36.5 | -63.5% |
| Cybin Inc. (CYBN) | 100 | 8.6 | -91.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: DRUG vs CMPS vs ATAI vs MNMD vs CYBN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: DRUG and CMPS are tied at the top with 1 category each (5-stock set) — the right choice depends on your priorities. COMPASS Pathways plc is the stronger pick specifically for capital preservation and lower volatility. ATAI, MNMD, and CYBN also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
DRUG
Bright Minds Biosciences Inc.
The Leading Pick
DRUG has the current edge in this matchup, primarily because of its strength in efficiency.
- -13.1% ROA vs CMPS's -106.8%
Best for: efficiency
CMPS
COMPASS Pathways plc
The Income Pick
CMPS is the #2 pick in this set and the best alternative if income & stability is your priority.
- beta 1.33
- Beta 1.33 vs DRUG's 1.87
Best for: income & stability
ATAI
Atai Beckley N.V
The Defensive Pick
ATAI ranks third and is worth considering specifically for sleep-well-at-night.
- Lower volatility, beta 1.48, Low D/E 21.2%, current ratio 3.21x
- -1.9% revenue growth vs DRUG's -305.3%
Best for: sleep-well-at-night
MNMD
Mind Medicine (MindMed) Inc.
The Long-Run Compounder
MNMD is the clearest fit if your priority is long-term compounding.
- 5.1% 10Y total return vs DRUG's 228.9%
- +214.0% vs CYBN's -1.9%
Best for: long-term compounding
CYBN
Cybin Inc.
The Growth Play
CYBN is the clearest fit if your priority is growth exposure and defensive.
- EPS growth 93.5%
- Beta 1.52, current ratio 7.75x
- 3.2% margin vs ATAI's -51.1%
Best for: growth exposure and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ATAI | -1.9% revenue growth vs DRUG's -305.3% |
| Quality / Margins | CYBN | 3.2% margin vs ATAI's -51.1% |
| Stability / Safety | CMPS | Beta 1.33 vs DRUG's 1.87 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | MNMD | +214.0% vs CYBN's -1.9% |
| Efficiency (ROA) | DRUG | -13.1% ROA vs CMPS's -106.8% |
DRUG vs CMPS vs ATAI vs MNMD vs CYBN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2024
Segment breakdown not available.
Segment breakdown not available.
DRUG vs CMPS vs ATAI vs MNMD vs CYBN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLDRUGLAGGINGCYBN
Who Leads Where
CMPS leads in 1 of 6 categories
DRUG leads 1 • ATAI leads 0 • MNMD leads 0 • CYBN leads 0 • 3 tied
Explore the data ↓CYBNCybin Inc.
0leads
MNMDMind Medicine (MindMe…
0leads
ATAIAtai Beckley N.V
0leads
CMPSCOMPASS Pathways plc
1leads
DRUGBright Minds Bioscien…
1leads
6 Total Categories
CATEGORYLEADERvs CMPSvs ATAIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CMPS1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
DRUG5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
Tied
—
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CMPS leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
ATAI and CYBN operate at a comparable scale, with $3M and $0 in trailing revenue.
| Metric | DRUGBright Minds Bios… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CYBNCybin Inc. |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $3M | $0 | $0 |
| EBITDAEarnings before interest/tax | -$12M | -$179M | -$103M | -$191M | -$147M |
| Net IncomeAfter-tax profit | -$11M | -$288M | -$154M | -$238M | -$123M |
| Free Cash FlowCash after capex | -$8M | -$157M | -$90M | -$174M | -$106M |
| Gross MarginGross profit ÷ Revenue | — | — | -2.6% | — | — |
| Operating MarginEBIT ÷ Revenue | — | — | -34.6% | — | — |
| Net MarginNet income ÷ Revenue | — | — | -51.1% | — | — |
| FCF MarginFCF ÷ Revenue | — | — | -29.9% | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | +17.7% | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -141.2% | -58.7% | -75.0% | -163.0% | -8.2% |
CMPS leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — DRUG and ATAI each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | DRUGBright Minds Bios… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CYBNCybin Inc. |
|---|---|---|---|---|---|
| Market CapShares × price | $864M | $902M | $964M | $2.0B | $304M |
| Enterprise ValueMkt cap + debt − cash | $804M | $774M | $971M | $1.8B | $205M |
| Trailing P/EPrice ÷ TTM EPS | -94.67x | -3.05x | -4.31x | -10.04x | -13.66x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | 3130.37x | — | — |
| Price / BookPrice ÷ Book value/share | 10.16x | — | 5.51x | 5.56x | 6.52x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Evenly matched — DRUG and ATAI each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
DRUG leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
DRUG delivers a -13.5% return on equity — every $100 of shareholder capital generates $-14 in annual profit, vs $-3 for CMPS. DRUG carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to ATAI's 0.21x. On the Piotroski fundamental quality scale (0–9), DRUG scores 4/9 vs ATAI's 2/9, reflecting mixed financial health.
| Metric | DRUGBright Minds Bios… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CYBNCybin Inc. |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -13.5% | -3.4% | -96.4% | -102.5% | -81.0% |
| ROA (TTM)Return on assets | -13.1% | -106.8% | -64.3% | -70.7% | -58.3% |
| ROICReturn on invested capital | — | — | -45.0% | -3.9% | -115.8% |
| ROCEReturn on capital employed | -31.8% | -2.5% | -50.4% | -52.2% | -54.1% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 | 2 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.00x | — | 0.21x | — | — |
| Net DebtTotal debt minus cash | -$83M | -$129M | $7M | -$258M | -$135M |
| Cash & Equiv.Liquid assets | $83M | $150M | $18M | $258M | $135M |
| Total DebtShort + long-term debt | $125,777 | $21M | $25M | $0 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -541.45x | -52.40x | -68.93x | -21.81x | — |
DRUG leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
Evenly matched — DRUG and MNMD each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in DRUG five years ago would be worth $38,216 today (with dividends reinvested), compared to $968 for CYBN. Over the past 12 months, MNMD leads with a +214.0% total return vs CYBN's -1.9%. The 3-year compound annual growth rate (CAGR) favors DRUG at 2.1% vs CYBN's -20.5% — a key indicator of consistent wealth creation.
| Metric | DRUGBright Minds Bios… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CYBNCybin Inc. |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +6.4% | +43.4% | +3.6% | +51.7% | -26.4% |
| 1-Year ReturnPast 12 months | +195.1% | +151.1% | +188.5% | +214.0% | -1.9% |
| 3-Year ReturnCumulative with dividends | +2860.5% | +11.0% | +99.5% | +510.3% | -49.8% |
| 5-Year ReturnCumulative with dividends | +282.2% | -72.4% | -79.8% | -57.9% | -90.3% |
| 10-Year ReturnCumulative with dividends | +228.9% | -67.6% | -47.7% | +512.1% | -99.7% |
| CAGR (3Y)Annualised 3-year return | +2.1% | +3.5% | +25.9% | +82.7% | -20.5% |
Evenly matched — DRUG and MNMD each lead in 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CMPS and MNMD each lead in 1 of 2 comparable metrics.
Risk & Volatility
CMPS is the less volatile stock with a 1.33 beta — it tends to amplify market swings less than DRUG's 1.87 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MNMD currently trades 98.1% from its 52-week high vs ATAI's 59.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | DRUGBright Minds Bios… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CYBNCybin Inc. |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.87x | 1.33x | 1.48x | 1.68x | 1.52x |
| 52-Week HighHighest price in past year | $123.75 | $10.21 | $6.75 | $21.09 | $9.83 |
| 52-Week LowLowest price in past year | $23.18 | $2.25 | $1.29 | $6.03 | $5.50 |
| % of 52W HighCurrent price vs 52-week peak | +71.8% | +92.0% | +59.4% | +98.1% | +62.0% |
| RSI (14)Momentum oscillator 0–100 | 57.6 | 68.1 | 51.5 | 64.9 | 35.5 |
| Avg Volume (50D)Average daily shares traded | 156K | 3.7M | 6.0M | 792K | 292K |
Evenly matched — CMPS and MNMD each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: DRUG as "Buy", CMPS as "Buy", ATAI as "Buy", MNMD as "Buy", CYBN as "Buy". Consensus price targets imply 199.3% upside for ATAI (target: $12) vs -3.3% for MNMD (target: $20).
| Metric | DRUGBright Minds Bios… | CMPSCOMPASS Pathways … | ATAIAtai Beckley N.V | MNMDMind Medicine (Mi… | CYBNCybin Inc. |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $136.50 | $17.83 | $12.00 | $20.00 | — |
| # AnalystsCovering analysts | 3 | 13 | 4 | 1 | 4 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CMPS leads in 1 of 6 categories (Income & Cash Flow). DRUG leads in 1 (Profitability & Efficiency). 3 tied.
Best OverallBright Minds Biosciences In… (DRUG)Leads 1 of 6 categories
Loading custom metrics...
DRUG vs CMPS vs ATAI vs MNMD vs CYBN: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is DRUG or CMPS or ATAI or MNMD or CYBN a better buy right now?
Analysts rate Bright Minds Biosciences Inc.
(DRUG) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — DRUG or CMPS or ATAI or MNMD or CYBN?
Over the past 5 years, Bright Minds Biosciences Inc.
(DRUG) delivered a total return of +282. 2%, compared to -90. 3% for Cybin Inc. (CYBN). Over 10 years, the gap is even starker: MNMD returned +512. 1% versus CYBN's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — DRUG or CMPS or ATAI or MNMD or CYBN?
By beta (market sensitivity over 5 years), COMPASS Pathways plc (CMPS) is the lower-risk stock at 1.
33β versus Bright Minds Biosciences Inc. 's 1. 87β — meaning DRUG is approximately 41% more volatile than CMPS relative to the S&P 500. On balance sheet safety, Bright Minds Biosciences Inc. (DRUG) carries a lower debt/equity ratio of 0% versus 21% for Atai Beckley N. V — giving it more financial flexibility in a downturn.
04Which is growing faster — DRUG or CMPS or ATAI or MNMD or CYBN?
On earnings-per-share growth, the picture is similar: Cybin Inc.
grew EPS 93. 5% year-over-year, compared to -1273. 3% for Mind Medicine (MindMed) Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — DRUG or CMPS or ATAI or MNMD or CYBN?
Bright Minds Biosciences Inc.
(DRUG) is the more profitable company, earning 0. 0% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DRUG leads at 0. 0% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — DRUG or CMPS or ATAI or MNMD or CYBN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is DRUG or CMPS or ATAI or MNMD or CYBN better for a retirement portfolio?
For long-horizon retirement investors, Mind Medicine (MindMed) Inc.
(MNMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+512. 1% 10Y return). Bright Minds Biosciences Inc. (DRUG) carries a higher beta of 1. 87 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MNMD: +512. 1%, DRUG: +228. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between DRUG and CMPS and ATAI and MNMD and CYBN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.